Innate Pharma Reaches Phase 1 Enrollment Milestone for IPH4502
Marseille, France | July 21, 2026 Innate Pharma SA has announced the completion of enrollment in the dose-escalation portion...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Marseille, France | July 21, 2026 Innate Pharma SA has announced the completion of enrollment in the dose-escalation portion...
JERUSALEM, Israel – May 5, 2026 Alpha Tau Medical Ltd. has announced that new clinical data evaluating Alpha DaRT®...
SAN MATEO, Calif., April 19, 2026 EpiBiologics has announced that the first patient has been dosed in its global...
RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
Kenilworth, N.J., October 29, 2025— Merck & Co., Inc. (NYSE: MRK), known as MSD outside the U.S. and Canada,...
